These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 25434595

  • 1. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA.
    Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
    [No Abstract] [Full Text] [Related]

  • 2. Nonincretin drugs in later-stage development.
    Zimmerman MP, Mehr SR.
    Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
    [No Abstract] [Full Text] [Related]

  • 3. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G, Cheng-Lai A.
    Cardiol Rev; 2014 Jan; 22(1):43-50. PubMed ID: 24304809
    [Abstract] [Full Text] [Related]

  • 4. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B, Mancini MC.
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [Abstract] [Full Text] [Related]

  • 5. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE, Gadde KM.
    Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
    [Abstract] [Full Text] [Related]

  • 6. Two new drugs approved for obesity.
    Johnson AM.
    S D Med; 2012 Sep; 65(9):356-7. PubMed ID: 23066610
    [No Abstract] [Full Text] [Related]

  • 7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Practical Use of Pharmacotherapy for Obesity.
    Igel LI, Kumar RB, Saunders KH, Aronne LJ.
    Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
    [Abstract] [Full Text] [Related]

  • 10. The FDA's assessment of two drugs for chronic weight management.
    Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C.
    N Engl J Med; 2012 Oct 25; 367(17):1577-9. PubMed ID: 23050510
    [No Abstract] [Full Text] [Related]

  • 11. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov 10; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract] [Full Text] [Related]

  • 12. ACS chemical neuroscience molecule spotlight on Qnexa.
    Mercer SL.
    ACS Chem Neurosci; 2011 Apr 20; 2(4):183-4. PubMed ID: 22778866
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacologic therapies for obesity.
    Kaplan LM.
    Gastroenterol Clin North Am; 2010 Mar 20; 39(1):69-79. PubMed ID: 20202580
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
    Halpern B, Faria AM, Halpern A.
    Expert Rev Clin Pharmacol; 2013 May 20; 6(3):235-41. PubMed ID: 23656337
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.